Genotype-Guided P2Y₁₂ Inhibitor Therapy after Percutaneous Coronary Intervention: A Bayesian Analysis

Keyphrases

• Inhibitor Therapy 100%
• Percutaneous Coronary Intervention 100%
• Bayesian Analysis 100%
• Credible Interval 100%
• P2Y12 Inhibitors 100%
• Genotype-guided 100%
• Informative Prior 46%
• Major Adverse Cardiovascular Events 38%
• Myocardial Infarction 30%
• Cardiovascular Mortality 30%
• Genotype-matched Therapy 30%
• Intervention Studies 23%
• Posterior Probability 23%
• Minor Bleeding 23%
• Stent Thrombosis 23%
• Major Bleeding 15%
• Usual Care 15%
• Clinically Significant 7%
• Antiplatelet Therapy 7%
• Randomized Clinical Trial 7%
• Clopidogrel Response 7%
• Antiplatelet 7%
• Bayesian Modeling 7%
• Clinical Benefit 7%
• Therapy Groups 7%
• Conventional Therapy 7%
• Risk Ratio 7%
• Probability Estimates 7%
• Major-minor 7%
• Post-percutaneous Coronary Intervention 7%
• Genotype-guided Antiplatelet Therapy 7%
• Cumulative Outcomes 7%
• Popular 7%
• Trial Population 7%

Medicine and Dentistry

• Percutaneous Coronary Intervention 100%
• Cardiovascular Disease 41%
• Cardiovascular System 33%
• Apoplexy 33%
• Myocardial Infarction 33%
• Bleeding 25%
• Antiplatelet 25%
• Intervention Trial 25%
• Stent Thrombosis 25%
• Randomized Clinical Trial 8%
• Group Therapy 8%
• Clopidogrel 8%